| AICHI PREFECTURE Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122995 | Anti-Inflammatory Agent and Cancer-Preventive Agent Comprising Canolol or Prodrug Thereof and Pharmaceutical, Cosmetic and Food Comprising the Same - An anti-inflammatory agent or cancer-preventive agent comprising 4-vinyl-2,6-dimethoxyphenol of the formula (1): or a PD thereof. | 05-17-2012 |
| 20100167321 | EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED EP-CAM-SPECIFIC CTL AND USE OF THE SAME - A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402. | 07-01-2010 |
| 20100137564 | POLYPEPTIDE OF N-ACETYLGLUCOSAMINE-6-O-SULFOTRANSFERASE AND DNA ENCODING THE SAME - A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below:
| 06-03-2010 |
| 20090305324 | CYTOTOXIC T-CELL EPITOPE PEPTIDES THAT SPECIFICALLY ATTACK EPSTEIN-BARR VIRUS-INFECTED CELLS AND USES THEREOF - The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells. | 12-10-2009 |
| 20090269582 | PROCESS FOR PRODUCING CORE/SHEATH CONJUGATE ELASTOMER FIBER - The present invention provides a process for producing a conjugate fiber that is excellent in strength, stretch elasticity, and transparency. The process includes a step (1) in which an elastomer resin (A) having stretching elasticity and an elastomer resin (B) having stretch elasticity, a permanent elongation of 25-70%, and a tensile elongation of 100-800% are separately melted and subjected to conjugate spinning using a conjugate spinneret having two nozzles so that the elastomer resin (A) forms a core and the elastomer resin (B) form a sheath; a step (2) in which the fiber obtained by composite spinning in the step (1) is heat-treated; and a step (3) in which the fiber heat-treated in the step (2) is stretched. | 10-29-2009 |
| 20090238863 | LIPOSOME COMPOSITION FOR INDUCTION OF IMMUNITY - It is an object of the present invention to provide a liposome composition which is able to allow the MHC class I and class II molecules of antigen-presenting cells to efficiently present an antigen substance. The present invention provides a liposome composition, which comprises an oligosaccharide-coated liposome and an antigen substance and is used to cause the MHC class I and class II molecules of an antigen-presenting cell to present an antigen peptide. | 09-24-2009 |
| 20090196858 | AMELIORATING AGENT FOR BRAIN DAMAGE - The present invention provides a pharmaceutical composition for ameliorating brain damage induced by oxygen deficiency, comprising a chondroitin sulfate-degrading enzyme and at least one of a neural stem cell(s) and a neural progenitor cell(s), as active ingredients. | 08-06-2009 |
| 20080268453 | Types of lymphoma and method for prognosis thereof - A method for determining the prognosis of a CD5+DLBCL patient and a CD5-DLBCL patient is provided. It is determined that, in the chromosomal DNA from a patient with lymphoma, (1) the prognosis of the CD5+DLBCL patient with amplification of 13 | 10-30-2008 |
